On June 13-14, 2023, the PQRI (Product Quality Research Institute) is hosting a special workshop in Washington DC focusing on the regulatory and technical challenges with respect to titanium dioxide (TiO2)’s use in pharmaceuticals.
The workshop will bring together material suppliers, the pharmaceutical industry, and regulatory experts to discuss the facts related to the safety of TiO2 in pharmaceutical applications. The impact of TiO2 from pharmaceutical applications in addition to the benefits and challenges of alternatives to TiO2 for use in various pharmaceutical dosage forms will also be discussed.
Expert speakers at the workshop include Dr David Lockley (Toxicology and Regulatory Defence Director at Venator Materials and Chair of the TDMA’s CLH Task Force) and Kevin Hughes (Regulatory Affairs and QA Manager at Colorcon Ltd and IPEC board member).
The outcomes of this workshop will be shared with regulators at the European Medicines Agency (EMA) and other regulatory agencies to help support the need for continued use of TiO2 in pharmaceutical applications given the absence of credible safety concerns.
This workshop is intended for professionals working in the following areas of the pharmaceutical industry:
- Excipient suppliers
- Ready-Made Color Mixture Suppliers
- Empty Hard Capsule Shell Suppliers
- Formulation Process Development Scientists and Engineers
- Manufacturing and Technical Services Representatives
- Quality Assurance and Quality Control Scientists
- Regulatory Affairs Scientists
- Regulatory Authorities
Registrations for this workshop are now open and will close at 15:00pm ET on Thursday, June 8, 2023.
